Enavogliflozin
drugOn this page
Also known as DWP-16001Dwp16001ODP-9401ODP9401US9034921E172
Summary
Enavogliflozin (CHEMBL3703921) is a phase-3 clinical-stage small molecule (ATC A10BK09) targeting SLC5A1 and SLC5A2; indicated across 2 conditions including diabetes mellitus and type 2 diabetes mellitus.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- ATC class: A10BK09
- Targets: 2 (SLC5A1, SLC5A2)
- Indications: 2 conditions
- Clinical trials: 29
- Chemistry: 446.9 Da · C24H27ClO6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3703921 |
| Name | Enavogliflozin |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 71076840 |
| ATC | A10BK09 |
| Molecular formula | C24H27ClO6 |
| Molecular weight | 446.9 |
| InChIKey | KORCWPOBTZTAFI-YVTYUBGGSA-N |
SMILES: C1CC1C2=CC=C(C=C2)CC3=CC(=C4CCOC4=C3Cl)[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O
IUPAC name: (2S,3R,4R,5S,6R)-2-[7-chloro-6-[(4-cyclopropylphenyl)methyl]-2,3-dihydro-1-benzofuran-4-yl]-6-(hydroxymethyl)oxane-3,4,5-triol
Also known as: DWP-16001, Dwp16001, Enavogliflozin, ODP-9401, ODP9401, US9034921, E172, ENAVOGLIFLOZIN
Patent coverage: 47 distinct patent families (147 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 105 (71%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| SLC5A1 | Sodium/glucose cotransporter 1 | Inhibition | 6.26 | 0% | P13866 |
| SLC5A2 | Sodium/glucose cotransporter 2 | Inhibition | 9.1 | 0.2% | P31639 |
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Sodium/glucose cotransporter 2, Sodium/glucose cotransporter 1.
Bioactivity
ChEMBL activities: 4 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| SLC5A2 | 9.34 | IC50 | 0.46 | nM | CHEMBL_ACT_24836697 |
| SLC5A2 | 9.33 | IC50 | 0.46 | nM | CHEMBL_ACT_17683148 |
| SLC5A2 | 9.33 | IC50 | 0.46 | nM | CHEMBL_ACT_26596274 |
| SLC5A1 | 6.45 | IC50 | 359 | nM | CHEMBL_ACT_24836711 |
Target pathways
Aggregated over 2 target gene(s): SLC5A1, SLC5A2.
Top Reactome pathways
11 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Disease | 2 | SLC5A1, SLC5A2 |
| Cellular hexose transport | 2 | SLC5A1, SLC5A2 |
| Transport of small molecules | 2 | SLC5A1, SLC5A2 |
| SLC-mediated transmembrane transport | 2 | SLC5A1, SLC5A2 |
| SLC transporter disorders | 2 | SLC5A1, SLC5A2 |
| Disorders of transmembrane transporters | 2 | SLC5A1, SLC5A2 |
| Defective SLC5A1 causes congenital glucose/galactose malabsorption (GGM) | 1 | SLC5A1 |
| Defective SLC5A2 causes renal glucosuria (GLYS1) | 1 | SLC5A2 |
| Intestinal absorption | 1 | SLC5A1 |
| Digestion and absorption | 1 | SLC5A1 |
| Intestinal hexose absorption | 1 | SLC5A1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| alpha-glucoside transport | 2 |
| sodium ion transport | 2 |
| renal D-glucose absorption | 2 |
| D-glucose import across plasma membrane | 2 |
| sodium ion import across plasma membrane | 2 |
| D-glucose transmembrane transport | 2 |
| monoatomic ion transport | 2 |
| transmembrane transport | 2 |
| intestinal D-glucose absorption | 1 |
| pentose transmembrane transport | 1 |
| fucose transmembrane transport | 1 |
| galactose transmembrane transport | 1 |
| myo-inositol transport | 1 |
| transepithelial water transport | 1 |
| intestinal hexose absorption | 1 |
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| diabetes mellitus | 3 | MONDO:0005015 | EFO:0000400 |
| type 2 diabetes mellitus | 3 | MONDO:0005148 | MONDO:0005148 |
Clinical trials
Total trials: 29.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 13 |
| PHASE4 | 7 |
| PHASE3 | 7 |
| PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05672836 | PHASE4 | RECRUITING | ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement |
| NCT06399835 | PHASE4 | RECRUITING | Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis |
| NCT06528262 | PHASE4 | RECRUITING | Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation |
| NCT06580717 | PHASE4 | RECRUITING | ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy |
| NCT06642623 | PHASE4 | RECRUITING | A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients |
| NCT06782139 | PHASE4 | RECRUITING | Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity |
| NCT07240844 | PHASE4 | NOT_YET_RECRUITING | Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy |
| NCT06027307 | PHASE3 | ACTIVE_NOT_RECRUITING | Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation |
| NCT06606093 | PHASE3 | NOT_YET_RECRUITING | Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients |
| NCT04632862 | PHASE3 | COMPLETED | The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus. |
| NCT05376969 | PHASE3 | COMPLETED | Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin |
| NCT05466643 | PHASE3 | UNKNOWN | A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus |
| NCT05505994 | PHASE3 | UNKNOWN | The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin |
| NCT06141980 | PHASE3 | UNKNOWN | Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus |
| NCT04014023 | PHASE2 | UNKNOWN | Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus |
| NCT06644404 | PHASE1 | NOT_YET_RECRUITING | Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults |
| NCT03364985 | PHASE1 | COMPLETED | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers |
| NCT04064073 | PHASE1 | COMPLETED | Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With Metformin in Healthy Male Adults (Phase 1 Study) |
| NCT04221399 | PHASE1 | UNKNOWN | Type 2 Diabetes Patients With Renal Impairment |
| NCT04343547 | PHASE1 | UNKNOWN | Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With DWC202001 and DWC202002 in Healthy Male Adults |
| NCT05192395 | PHASE1 | COMPLETED | A Crossover Study of DWJ1525 to Evaluate the Safety and Pharmacokinetic Properties in Healthy Volunteers |
| NCT05207176 | PHASE1 | UNKNOWN | Study to Evaluate the Safety and PK Properties of DWP16001 in Healthy Subjects With Various Ethnicities |
| NCT05321732 | PHASE1 | UNKNOWN | The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults |
| NCT05500898 | PHASE1 | UNKNOWN | Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults |
| NCT05737771 | PHASE1 | UNKNOWN | To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination |
| NCT05747664 | PHASE1 | UNKNOWN | To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic Function |
| NCT05797922 | PHASE1 | UNKNOWN | To Evaluate the Effect of Food on the Safety and PK Characteristics of DWP16001 in Healthy Adult Volunteers |
| NCT07213310 | PHASE1 | COMPLETED | Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults |
| NCT05926414 | Not specified | ACTIVE_NOT_RECRUITING | To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
16 molecules share ≥1 primary target. Top 16 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| BEXAGLIFLOZIN | ChEMBL + PubChem | Phase 4 (approved) | SLC5A1, SLC5A2 |
| Canagliflozin | ChEMBL + PubChem | Phase 4 (approved) | SLC5A1, SLC5A2 |
| EMPAGLIFLOZIN | ChEMBL + PubChem | Phase 4 (approved) | SLC5A1, SLC5A2 |
| ERTUGLIFLOZIN | ChEMBL + PubChem | Phase 4 (approved) | SLC5A1, SLC5A2 |
| SOTAGLIFLOZIN | ChEMBL + PubChem | Phase 4 (approved) | SLC5A1, SLC5A2 |
| DAPAGLIFLOZIN | ChEMBL | Phase 4 (approved) | SLC5A1, SLC5A2 |
| IPRAGLIFLOZIN | ChEMBL | Phase 4 (approved) | SLC5A1, SLC5A2 |
| TOFOGLIFLOZIN | ChEMBL | Phase 4 (approved) | SLC5A1, SLC5A2 |
| HENAGLIFLOZIN | ChEMBL | Phase 3 | SLC5A1, SLC5A2 |
| LICOGLIFLOZIN | ChEMBL | Phase 2 | SLC5A1, SLC5A2 |
| LUSEOGLIFLOZIN | ChEMBL | Phase 2 | SLC5A1, SLC5A2 |
| REMOGLIFLOZIN ETABONATE | ChEMBL | Phase 2 | SLC5A1, SLC5A2 |
| SERGLIFLOZIN ETABONATE | ChEMBL | Phase 2 | SLC5A1, SLC5A2 |
| MIZAGLIFLOZIN | ChEMBL | Phase 2 | SLC5A1 |
| YM-543 FREE ACID | ChEMBL | Phase 2 | SLC5A2 |
| Phlorizin | PubChem | Approved | SLC5A1 |
Related Atlas pages
- Genes: SLC5A1, SLC5A2
- Diseases: diabetes mellitus, type 2 diabetes mellitus
- Drugs: Bexagliflozin, Canagliflozin, Empagliflozin, Ertugliflozin, Sotagliflozin, Dapagliflozin, Ipragliflozin, Tofogliflozin, Henagliflozin